{"filings":[{"id":2880559,"accession_number":"0001193125-26-391952","cik":1657677,"company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","form_type":"8-K","filed_at":"2026-09-15T20:15:35+00:00","items":["7.01"],"status":"ready","headline":"Parabilis to present updated zolucatetide data in desmoid tumors at ESMO 2026","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Updated Phase 1/2 zolucatetide data in desmoid tumors to be presented at ESMO Congress 2026 in Madrid.","Oral presentation scheduled Oct 24, 2:45pm CEST in sarcoma-focused Proffered Paper session.","Company updates guidance to reflect intention to present data; no numbers disclosed yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2631282,"accession_number":"0001193125-26-380171","cik":1657677,"company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","form_type":"8-K","filed_at":"2026-09-02T20:05:15+00:00","items":["5.02"],"status":"ready","headline":"Parabilis Medicines CMO Fawzi Benzaghou to depart effective Sept 30, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Medical Officer Fawzi Benzaghou, M.D. and company mutually agreed to his transition, effective September 30, 2026.","Dr. Benzaghou will receive severance benefits pursuant to his employment agreement.","No replacement CMO has been named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2466077,"accession_number":"0001193125-26-365132","cik":1657677,"company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","form_type":"8-K","filed_at":"2026-08-25T20:10:15+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Parabilis Medicines appoints Craig Tendler to board as independent Class II director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to nine; Craig Tendler, M.D., appointed Class II director on Aug 22, 2026, term to 2028.","Receives stock option for 20,294 shares at $39.36/share, vesting monthly over 3 years.","Annual retainer of $40,000 for board plus $7,500 for Science & Technology Committee service.","Tendler brings 30+ years oncology development incl. two decades at J&J; joins Science & Technology Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2226156,"accession_number":"0001193125-26-347869","cik":1657677,"company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","form_type":"8-K","filed_at":"2026-08-13T11:19:04+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Parabilis Q2 net loss $52.5M; $1.1B cash after $770.5M IPO; Regeneron deal up to $2.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $52.5M in Q2 2026 vs $34.8M prior year; R&D $39.4M, G&A $11.7M.","Cash $1.1B as of June 30, 2026 (vs $27.7M Dec 31, 2025) after $770.5M IPO at $20.00/share; funds ops into 2030.","Regeneron collaboration: $125M received ($50M upfront + $75M equity); up to $2.2B milestones plus low double-digit tiered royalties for Antibody-Helicon Conjugates.","Zolucatetide: ESMO 2026 abstract accepted; FDA alignment Q4 2026; Phase 3 desmoid trial initiation H1 2027; FAP cohort H2 2026.","Leadership: Helen Ho (Chief Business & Strategy Officer), Tom Kotarakos (CFO), Alan M. Sebulsky to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1000240,"accession_number":"0001193125-26-267550","cik":1657677,"company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","form_type":"8-K","filed_at":"2026-06-11T20:12:52+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Regeneron invests $75M in Parabilis at 10% discount to IPO price in concurrent private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchased 4,166,666 shares at 90% of $20 IPO price ($18/share); total $75M.","Private placement closed June 11, 2026, alongside IPO.","Regeneron granted piggyback registration rights on the shares.","Charter amended to authorize 600M voting and 200M non-voting common shares, eliminate preferred.","Transaction signals strategic backing from a major biopharma partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}